Format

Send to:

Choose Destination
See comment in PubMed Commons below
Womens Health (Lond Engl). 2011 Mar;7(2):151-8. doi: 10.2217/whe.11.9.

Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding.

Author information

  • 1Rochester General Hospital, 1425 Portland Ave, Rochester, NY 14621, USA. andrealukes@cwrwc.com

Abstract

Tranexamic acid, a synthetic lysine derivative, is an antifibrinolytic drug that prevents the breakdown of fibrin by competitively blocking binding sites of plasminogen. Tranexamic acid is often considered a first-line treatment for the management of heavy menstrual bleeding (HMB). A new oral formulation of tranexamic acid provides a nonhormonal HMB therapy that is safe, effective and well tolerated; is administered only during menstruation; addresses the excessive fibrinolysis implicated in many cases of HMB; and improves women's health-related quality of life by reducing limitations on physical, social and leisure activities. This article provides a summary of the clinical development, therapeutic efficacy and tolerability profile of this novel formulation of tranexamic acid for the treatment of HMB.

PMID:
21410342
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk